rs16928751 — ADIPOR2 ADIPOR2 CVD co-association variant

ADIPOR2 rs16928751: A Haplotype Tag for Cardiovascular Risk in Adiponectin Signaling

Adiponectin is one of the body's most important metabolic hormones, produced by fat tissue and acting primarily through two receptors: ADIPOR1 in skeletal muscle and ADIPOR2 in the liver. In a paradox central to metabolic disease, adiponectin levels fall precisely as body fat rises — removing the hormone's protection at the moment it is needed most. rs16928751 sits in exon 7 of the ADIPOR2 gene and produces a synonymous codon change (CAG to CAA, both encoding glutamine at position 265). No amino acid is altered, yet the A allele was co-identified alongside three other ADIPOR2 variants as associated with cardiovascular disease risk in the Finnish Diabetes Prevention Study (DPS)¹¹ Finnish Diabetes Prevention Study (DPS)
A randomized lifestyle intervention trial enrolling 484 participants with impaired glucose tolerance, followed for a median of 10.2 years for cardiovascular events and 7 years for diabetes progression. The most likely interpretation is that rs16928751 tags an extended ADIPOR2 risk haplotype rather than having independent functional impact — it co-segregates with variants that measurably reduce receptor expression.

The Mechanism

A synonymous variant changes a codon without altering the encoded amino acid. For most such variants, there is no biological consequence. However, synonymous changes in coding sequence can influence mRNA stability, translational speed, or splicing efficiency, particularly when the altered codon is used at different frequencies across tissues. In ADIPOR2's case, the A allele at rs16928751 sits near the AMPK and PPARα signaling domain²² AMPK and PPARα signaling domain
AMP-activated protein kinase and peroxisome proliferator-activated receptor alpha — two central metabolic regulators activated when adiponectin binds ADIPOR2 in liver cells, suppressing fat synthesis and enhancing fatty acid oxidation. Whether the synonymous change affects ADIPOR2 mRNA levels or translation efficiency has not been directly tested, but its co-association with intronic variants that do reduce ADIPOR2 expression (rs1058322 T allele carriers show measurably lower mRNA in peripheral blood cells, PMID 21943112) suggests it marks the same risk haplotype rather than acting independently.

The Evidence

The Finnish DPS genotyped eight ADIPOR2 variants in 484 individuals with impaired glucose tolerance. Four showed nominal association with cardiovascular events, including rs16928751. In the joint multi-SNP model, however, only rs11061937 (p = 0.014) and rs1058322 (p = 0.020) retained independent significance — rs16928751 and rs10848554 were attenuated, consistent with co-segregation on the same risk haplotype rather than independent contributions. The study did not report individual hazard ratios for rs16928751 in the abstract and the variant did not survive multi-variant correction, placing its independent effect in the emerging category³³ emerging category
Single candidate study, moderate sample size; association was attenuated in the multi-SNP model, suggesting it tags rather than drives the haplotype risk.

The broader ADIPOR2 biology is well-established. Receptor knockout experiments confirm that ADIPOR2 loss selectively impairs hepatic fatty acid oxidation and insulin sensitivity. A synthetic ADIPOR agonist, AdipoRon, activates both ADIPOR1 and ADIPOR2 and extends lifespan and insulin sensitivity in obese diabetic mice⁴⁴ synthetic ADIPOR agonist, AdipoRon, activates both ADIPOR1 and ADIPOR2 and extends lifespan and insulin sensitivity in obese diabetic mice
Okada-Iwabu et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature, 2013, confirming the pathway as a genuine therapeutic target. ADIPOR2 is also selectively downregulated in visceral obesity⁵⁵ selectively downregulated in visceral obesity
Hepatic AdipoR2 expression falls in obesity while AdipoR1 is preserved; reduced AdipoR2 contributes to insulin resistance through impaired APPL1 signaling, meaning that visceral fat accumulation compounds any haplotype-level expression deficit.

Practical Actions

Because rs16928751 is most likely a haplotype tag rather than an independent functional driver, the actionable guidance mirrors the broader ADIPOR2 risk cluster: strategies that raise circulating adiponectin (omega-3 supplementation, replacing saturated fat with polyunsaturated fat) and monitoring that catches early metabolic drift before cardiovascular consequences emerge. Carriers of the A allele who also carry risk alleles at rs1058322 or rs11061937 should treat those variants as the primary actionable signals and apply the same cardiometabolic monitoring and dietary guidance.

Interactions

rs16928751 was co-analyzed with rs11061937, rs1058322, and rs10848554 in the Finnish DPS. The four SNPs collectively define a CVD-risk region of the ADIPOR2 locus; their independent effects diminish substantially in the multi-SNP model, suggesting shared haplotype rather than additive independent signals. Individuals carrying the A allele at rs16928751 alongside the T allele of rs1058322 or the C allele of rs11061937 — the two variants that did survive multi-SNP correction — are most likely to carry the full-length CVD-risk ADIPOR2 haplotype. For those individuals, the monitoring and dietary actions recommended for rs1058322 or rs11061937 apply directly.